Drug Profile
KN 002 - Kinaset Therapeutics/Vectura
Alternative Names: KN-002 - Kinaset Therapeutics/Vectura; VR-588Latest Information Update: 11 Jul 2022
Price :
$50
*
At a glance
- Originator Vectura
- Developer Imperial College of Science, Technology and Medicine; Kinaset Therapeutics; Vectura
- Class Anti-inflammatories; Antiasthmatics; Small molecules
- Mechanism of Action Janus kinase 1 inhibitors; Janus kinase 3 inhibitors; Janus kinase-2 inhibitors; TRPV1 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Asthma; Chronic obstructive pulmonary disease
- No development reported Inflammation
Most Recent Events
- 07 Jul 2022 Kinaset Therapeutics plans a phase II trial for Asthma
- 05 Sep 2021 Pharmacodynamics data from a preclinical study in Asthma presented at the 31st Annual Congress of the European Respiratory Society (ERS-2021)
- 30 Jul 2021 Phase-I clinical trials in Chronic obstructive pulmonary disease in United Kingdom (PO) (NCT05006521) (Kinaset Therapeutics pipeline, May 2023)